These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22796577)

  • 1. Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.
    Collin N; Assumpção TC; Mizurini DM; Gilmore DC; Dutra-Oliveira A; Kotsyfakis M; Sá-Nunes A; Teixeira C; Ribeiro JM; Monteiro RQ; Valenzuela JG; Francischetti IM
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2185-98. PubMed ID: 22796577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alboserpin, a factor Xa inhibitor from the mosquito vector of yellow fever, binds heparin and membrane phospholipids and exhibits antithrombotic activity.
    Calvo E; Mizurini DM; Sá-Nunes A; Ribeiro JM; Andersen JF; Mans BJ; Monteiro RQ; Kotsyfakis M; Francischetti IM
    J Biol Chem; 2011 Aug; 286(32):27998-8010. PubMed ID: 21673107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.
    Francischetti IM; Valenzuela JG; Andersen JF; Mather TN; Ribeiro JM
    Blood; 2002 May; 99(10):3602-12. PubMed ID: 11986214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis.
    Francischetti IM; Mather TN; Ribeiro JM
    Thromb Haemost; 2004 May; 91(5):886-98. PubMed ID: 15116248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo.
    Ma D; Mizurini DM; Assumpção TC; Li Y; Qi Y; Kotsyfakis M; Ribeiro JM; Monteiro RQ; Francischetti IM
    Blood; 2013 Dec; 122(25):4094-106. PubMed ID: 24159172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
    Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
    Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of prothrombinase by human secretory phospholipase A2 involves binding to factor Xa.
    Mounier CM; Hackeng TM; Schaeffer F; Faure G; Bon C; Griffin JH
    J Biol Chem; 1998 Sep; 273(37):23764-72. PubMed ID: 9726985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.
    Chen W; Carvalho LP; Chan MY; Kini RM; Kang TS
    J Thromb Haemost; 2015 Feb; 13(2):248-61. PubMed ID: 25418421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.
    Andersen JF; Lei H; Strayer EC; Kanai T; Pham V; Pan XZ; Alvarenga PH; Gerber GF; Asojo OA; Francischetti IMB; Brodsky RA; Valenzuela JG; Ribeiro JMC
    Blood; 2023 Jun; 141(25):3109-3121. PubMed ID: 36947859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A factor Xa-directed anticoagulant from the salivary glands of the yellow fever mosquito Aedes aegypti.
    Stark KR; James AA
    Exp Parasitol; 1995 Nov; 81(3):321-31. PubMed ID: 7498429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guianensin, a
    Valenzuela-Leon PC; Campos Chagas A; Martin-Martin I; Williams AE; Berger M; Shrivastava G; Paige AS; Kotsyfakis M; Tirloni L; Calvo E
    Front Immunol; 2023; 14():1163367. PubMed ID: 37469515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
    Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
    Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
    Oe Y; Hayashi S; Fushima T; Sato E; Kisu K; Sato H; Ito S; Takahashi N
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1525-33. PubMed ID: 27283743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
    Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
    J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
    Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative Three-Step Microwave-Promoted Synthesis of
    Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade.
    Nazareth RA; Tomaz LS; Ortiz-Costa S; Atella GC; Ribeiro JM; Francischetti IM; Monteiro RQ
    Thromb Haemost; 2006 Jul; 96(1):7-13. PubMed ID: 16807644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joannsin, a novel Kunitz-type FXa inhibitor from the venom of Prospirobolus joannsi.
    Luan N; Zhou C; Li P; Ombati R; Yan X; Mo G; Rong M; Lai R; Duan Z; Zheng R
    Thromb Haemost; 2017 Jun; 117(6):1031-1039. PubMed ID: 28276572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.